



CAPLIN POINT LABORATORIES LTD.

CIN : L24231TN1990PLC019053

Regd. Off. : "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone : +91 44 28156653, 28156905
Fax : +91 44 28154952 E-mail : info@caplinpoint.net Website : www.caplinpoint.net

06.02.2017

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

**SUB: UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED DECEMBER
31,2016**

The Board of Directors of the Company at their meeting held today had approved the Un-audited Financial Results of the Company for the Quarter/Nine Months ended December 31,2016. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We herewith enclose the Unaudited Financial Results for the quarter/nine months ended December 31,2016 together with limited review report.

Kindly Acknowledge its receipt.

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2016

Part I	Particulars	Quarter Ended			Year to date		9 Months period and Financial Year ended
		31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	
		(1)	(2)	(3)	(4)	(5)	(6)
		(Unaudited)					(Audited)
		Rs. In Lakhs					
1	Income						
	a. Net Sales/ income from operations (Net of Excise Duty)	8,767.44	8,132.10	7,552.02	24,619.63	21,502.15	22,704.36
	b. Foreign Exchange Fluctuation Gain	68.90	29.29	-	98.19	-	-
	c. Share of profits in LLP	94.86	100.63	164.26	430.49	518.13	424.86
	d. Total	8,931.20	8,262.02	7,716.28	25,148.31	22,020.28	23,129.22
2	Expenditure						
	a. Cost of materials consumed	1,318.97	1,694.95	1,000.56	4,758.37	3,059.17	3,897.53
	b. Purchase of Stock-in-Trade	2,630.97	2,354.03	2,614.95	7,435.37	7,943.07	7,806.63
	c. Change in inventories of Finished Goods, work in progress and stock in trade	(134.75)	42.67	164.76	(127.76)	142.26	(30.82)
	d. Employees benefit expenses	851.86	692.94	581.01	2,183.21	1,650.26	1,757.04
	e. Depreciation & Amortisation Expenses	297.25	259.41	264.14	822.93	782.58	729.91
	f. Foreign Exchange Fluctuation Loss	-	-	196.43	2.95	375.24	321.83
	g. Other Expenditure	1,760.81	1,282.63	948.67	4,161.08	2,733.38	3,089.69
	h. Total Expenses	6,725.11	6,326.64	5,770.52	19,236.16	16,685.97	17,571.81
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	2,206.09	1,935.38	1,945.76	5,912.15	5,334.32	5,557.41
4	Other Income	147.53	162.79	115.23	444.09	278.44	347.32
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	2,353.62	2,098.17	2,060.99	6,356.24	5,612.75	5,904.73
6	Finance cost	20.34	5.07	4.93	27.78	17.53	10.82
7	Profit(+)/Loss(-) before Tax (5-6)	2,333.28	2,093.10	2,056.06	6,328.46	5,595.22	5,893.91
8	Provision for Taxation	450.46	495.33	457.59	1,328.98	1,261.40	1,264.71
	Provision for Taxation - earlier years	-	-	-	-	-	-
	Deferred Tax Provision	112.92	(84.69)	0.85	103.04	46.69	264.11
	Mat Credit Entitlement	-	-	-	-	-	(223.41)
9	Net Profit(+)/Loss(-) for the period (7-8)	1,769.90	1,682.45	1,597.62	4,896.44	4,287.13	4,588.50
10	Other Comprehensive Income	(0.20)	0.22	(0.05)	1.70	(0.14)	(59.48)
11	Total Comprehensive Income(9+10)	1,769.70	1,682.67	1,597.57	4,898.15	4,286.99	4,529.02
12	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs Rs 2/- each wef 20 Oct 2016)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						11,573.96
14	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 10/- per Equity share (prior to sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	-	11.14	10.57	32.42	28.37	29.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	-	11.14	10.57	32.42	28.37	29.99
	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 2/- per Equity share (post sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	2.34	2.23	2.11	6.48	5.67	5.99
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	2.34	2.23	2.11	6.48	5.67	5.99

	Part II				
		"Dec 2016	"Sep 2016	"Dec 2015	"Mar 2016
A	PARTICULARS OF SHARE HOLDING				
15	Public Shareholding				
	- Number of Shares	23356235	4671247	4863247	4863247
	- Percentage of Shareholding	30.91%	30.91%	32.19%	32.19%
16	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the company)				
	b) Non-encumbered				
	- Number of Shares	52193765	10438753	10246753	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	69.09%	69.09%	67.81%	67.81%

B	Particulars	3 months ended 31-12-2016
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	4
	Received during the quarter	139
	Disposed of during the quarter	139
	Remaining unresolved at the end of the quarter	4

Notes :

- 1) The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 06 February 2017.
- 2) Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended 31st December 2016.
- 3) The Ind AS compliant corresponding figures for the nine months ended 31st December 2016 and financial year ended 31 March 2016 and corresponding previous nine months ended 31st December 2015 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the nine months presented are as under:

Standalone		
Particulars	For the nine months ended 31.12.2015	For the nine months period and financial year ended 31.03.2016
Net profit under previous GAAP	4,287.13	4,532.53
Actuarial (gain) / Loss on employee defined benefit funds recognised in Other Comprehensive income	-	55.95
Net profit for the period under Ind AS	4,287.13	4,588.48
Other Comprehensive Income	(0.14)	(59.48)
Total Comprehensive Income under Ind AS	4,286.99	4,529.00


- 4) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary items.
- 5) From 1st April 2016, Company has adopted accounting standards notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- 6) Under Accounting Standard, financial assets were measured at lower of cost and realisable value. Under Ind AS such financial assets are recognised and measured at fair value. Impact of fair value change as on the date of transition, i.e., 1st April 2015, is recognised in reserves and changes thereafter are recognised in Statement of Profit and Loss or Other Comprehensive Income, as the case may be.
- 7) Employee benefits - Actuarial gains and losses on defined benefit plans: Under Accounting Standard all actuarial gains and losses were recognised in the Statement of profit and loss. Under Ind AS these are recognised in Other Comprehensive Income.
- 8) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each. Accordingly, number of paid up shares of the Company stand at 7,55,50,000.
- 9) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director

Place : Chennai
Date : 06.02.2017

For CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FIRM REGN.No.0049155


K. PARTHASARATHY
PARTNER
MEMB.No.018394





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

G. CHELLA KRISHNA
M.Com., FCA, PGPM

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Standalone Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To
The Board of Directors
Caplin point Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of **Caplin Point Laboratories Limited** for the quarter ended 31st December 2016, being submitted by the company pursuant of the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue report on these financial statements based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information



required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : 6th February, 2017



For M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036


K. PARTHASARATHY
Partner
Membership No: 018394

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2016

Part I		Quarter Ended			Year to date		9 Months period and Financial Year ended
	Particulars	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
		(1)	(2)	(3)	(4)	(5)	(6)
		(Unaudited)					(Audited)
		Rs. In Lakhs					
1	Income						
	a. Net Sales/ income from operations (Net of Excise Duty)	10,279.04	9,572.20	7,926.94	28,359.14	22,693.91	23,872.17
	b. Foreign Exchange Fluctuation Gain	65.90	32.29	-	98.19	-	-
	c. Total	10,344.94	9,604.49	7,926.94	28,457.33	22,693.91	23,872.17
2	Expenditure						
	a. Cost of materials consumed	1,338.97	1,694.95	1,161.52	4,788.37	3,553.78	4,408.34
	b. Purchase of Stock-in-Trade	2,985.06	3,045.02	2,590.10	8,766.14	7,903.14	7,776.16
	c. Change in inventories of Finished Goods, work in progress and stock in trade	(136.88)	57.19	151.60	(127.76)	154.79	(68.04)
	d. Employees benefit expenses	852.33	695.94	593.44	2,192.88	1,679.21	1,790.72
	e. Depreciation & Amortisation Expenses	298.05	259.41	274.11	830.74	797.52	747.78
	f. Foreign Exchange Fluctuation Loss	-	-	178.76	2.95	334.96	293.36
	g. Other Expenditure	2,059.27	1,294.68	985.55	4,516.59	2,847.62	3,217.64
	h. Total Expenses	7,396.80	7,047.19	5,935.07	20,969.91	17,271.01	18,165.96
3	Profit(+)/Loss(-) before other income and finance cost (1-2)	2,948.14	2,557.30	1,991.86	7,487.42	5,422.89	5,706.20
4	Other Income	153.83	167.09	121.95	460.14	302.89	365.95
5	Profit(+)/Loss(-) before finance costs and Tax (3+4)	3,101.97	2,724.39	2,113.82	7,947.56	5,725.79	6,072.15
6	Finance cost	21.69	5.37	5.08	30.48	17.76	11.01
7	Profit(+)/Loss(-) before Tax (5-6)	3,080.28	2,719.02	2,108.74	7,917.08	5,708.03	6,061.14
8	Provision for Taxation	575.46	545.33	497.59	1,538.98	1,371.40	1,430.61
	Provision for Taxation - earlier years	-	-	-	-	-	-
	Deferred Tax Provision	112.92	(84.69)	0.85	103.04	46.69	264.11
	Mat Credit Entitlement	-	-	-	-	-	(266.44)
9	Net Profit(+)/Loss(-) for the period (7-8)	2,391.90	2,258.37	1,610.30	6,275.06	4,289.94	4,632.86
10	Other Comprehensive Income	(0.20)	0.22	(0.05)	1.70	(0.14)	(59.48)
11	Total Comprehensive Income(9+10)	2,391.70	2,258.59	1,610.25	6,276.76	4,289.80	4,573.38
12	Minority Interest	(2.39)	(2.26)	(0.16)	(6.28)	(4.29)	(0.43)
13	Net Profit(+)/Loss(-) for the period after minority interest (11-12)	2,389.31	2,256.33	1,610.09	6,270.49	4,285.51	4,572.95
13	Paid up Equity Share Capital (Face value of the share - Rs 10/- each has been sub-divided into 5 equity shares of Rs Rs 2/- each wef 20 Oct 2016)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
14	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						11,573.88
15	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 10/- per Equity share (prior to sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	-	14.93	10.66	41.50	28.36	30.28
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	-	14.93	10.66	41.50	28.36	30.28
	Earnings/(Loss) Per Share (EPS) (Not annualised)based on face value Rs 2/- per Equity share (post sub division of shares)						
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	3.16	2.99	2.13	8.30	5.67	6.05
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	3.16	2.99	2.13	8.30	5.67	6.05

Part II					
		Dec 2016	Sep 2016	Dec 2015	Mar 2016
A	PARTICULARS OF SHARE HOLDING				
15	Public Shareholding				
	- Number of Shares	23356235	4671247	4863247	4863247
	- Percentage of Shareholding	30.91%	30.91%	32.19%	32.19%
16	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the company)				
	b) Non-encumbered				
	- Number of Shares	52193765	10438753	10246753	10246753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	69.09%	69.09%	67.81%	67.81%

B	Particulars	3 months ended 31-12-2016
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	4
	Received during the quarter	139
	Disposed of during the quarter	139
	Remaining unresolved at the end of the quarter	4

Notes :

- 1) The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 06 February 2017.
- 2) Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended 31st December 2016.
- 3) The Ind AS compliant corresponding figures for the nine months ended 31st December 2016 and financial year ended 31 March 2016 and corresponding previous nine months ended 31st December 2015 have not been subjected to review/audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the nine months presented are as under:

Consolidated		
Particulars	Amount in Indian Rupees Lakhs	
	For the nine months ended 31.12.2015	For the nine months period and financial year ended 31.03.2016
Net profit under previous GAAP	4,289.94	4,576.91
Actuarial (gain) / Loss on employee defined benefit funds recognised in Other Comprehensive income	-	55.95
Net profit for the period under Ind AS	4,289.94	4,632.86
Other Comprehensive Income	(0.14)	(59.48)
Total Comprehensive Income under Ind AS	4,289.80	4,573.38

- 4) The consolidated interim financial results of the company and its subsidiaries have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- 5) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary items.
- 6) From 1st April 2016, Company has adopted accounting standards notified under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- 7) Under Accounting Standard, financial assets were measured at lower of cost and realisable value. Under Ind AS such financial assets are recognised and measured at fair value. Impact of fair value change as on the date of transition, i.e., 1st April 2015, is recognised in reserves and changes thereafter are recognised in the statement of Profit and Loss or Other Comprehensive Income, as the case may be.
- 8) Employee benefits - Actuarial gains and losses on defined benefit plans: Under Accounting Standard all actuarial gains and losses were recognised in Statement of profit and loss. Under Ind AS these are recognised in Other Comprehensive Income.
- 9) With effect from 20th Oct, 2016 the Equity shares of the Company having face value of Rs 10/- each has been sub divided into 5 shares of Rs 2/- each. Accordingly, number of paid up shares of the Company stand at 7,55,50,000.
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr. Sridhar Ganesan
Managing Director

Place : Chennai
Date : 06.02.2017

For C N G S N & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FIRM REGN.No.0049155


K. PARTHASARATHY
PARTNER

MEMB.No.018394





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

S. NEELAKANTAN
B.Com., FCA

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

V. VIVEK ANAND
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

G. CHELLA KRISHNA
M.Com., FCA, PGPM

K. PARTHASARATHY
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Consolidated Financial Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To
The Board of Directors
Caplin Point Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Caplin Point Laboratories Limited** ("the company"), its subsidiary (the company, its subsidiary constitute "the group") for the quarter ended 31st December 2016, being submitted by the company pursuant to the requirements of regulations 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue report on these financials statements based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of




Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : 6th February, 2017



For M/s CNGSN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
Firm Registration No: 004915S/S200036


K. Parthasarathy
Partner
Membership No: 018394